Investors Bid BioLife Solutions (NASDAQ:BLFS) up US$53m Despite Increasing Losses YoY, Taking Five-year CAGR to 11%
Investors Bid BioLife Solutions (NASDAQ:BLFS) up US$53m Despite Increasing Losses YoY, Taking Five-year CAGR to 11%
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the BioLife Solutions, Inc. (NASDAQ:BLFS) share price is up 71% in the last five years, that's less than the market return. However, more recent buyers should be happy with the increase of 57% over the last year.
當你買入並持有一隻股票時,肯定希望它能提供正向回報。但更重要的是,你可能希望它的漲幅超過市場平均水平。不幸的是,對於股東來說,雖然BioLife Solutions, Inc.(納斯達克:BLFS)的股價在過去五年中上漲了71%,但這低於市場回報。然而,最近的買家應該對過去一年57%的漲幅感到滿意。
Since the stock has added US$53m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.
由於這隻股票在過去一週內市值增加了5300萬美元,我們來看看基本表現是否推動了長期回報。
Given that BioLife Solutions didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.
鑑於BioLife Solutions在過去十二個月內沒有盈利,我們將關注營業收入的增長,以快速了解其業務發展。一般來說,尚未盈利的公司預計每年都能實現營業收入的增長,而且增長速度要快。這是因爲快速的營業收入增長可以容易地推斷出利潤,通常是相當可觀的。
In the last 5 years BioLife Solutions saw its revenue grow at 29% per year. That's well above most pre-profit companies. It's nice to see shareholders have made a profit, but the gain of 11% over the period isn't that impressive compared to the overall market. You could argue the market is still pretty skeptical, given the growing revenues. Arguably this falls in a potential sweet spot - modest share price gains but good top line growth over the long term justifies investigation, in our book.
在過去5年中,BioLife Solutions的營業收入每年增長了29%。這遠高於大多數尚未盈利的公司。看到股東獲得盈利是件好事,但在此期間11%的收益與整體市場相比並不算令人印象深刻。可以說,考慮到收入的增長,市場依然相當懷疑。這可以說處於一個潛在的甜蜜點——適度的股價上漲,但較好的長期營業收入增長值得我們深究。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
以下圖像顯示了公司的營業收入和盈利(隨時間變化)(單擊以查看準確的數字)。
Take a more thorough look at BioLife Solutions' financial health with this free report on its balance sheet.
通過這份免費的財務報告,更深入地了解BioLife Solutions的財務健康狀況。
A Different Perspective
不同的視角
We're pleased to report that BioLife Solutions shareholders have received a total shareholder return of 57% over one year. That gain is better than the annual TSR over five years, which is 11%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that BioLife Solutions is showing 1 warning sign in our investment analysis , you should know about...
我們很高興地報告,BioLife Solutions的股東在一年內的總股東回報達到了57%。這一增幅超出了五年的年化總股東回報率11%。因此,最近公司周圍的情緒似乎是積極的。擁有樂觀觀點的人可能會認爲,最近的總股東回報率改善表明業務本身隨着時間的推移在改善。我發現,從長期來看,查看股價作爲業績表現的代理指標是非常有趣的。但要真正獲得洞察,我們還需要考慮其他信息。即便如此,請注意,BioLife Solutions在我們的投資分析中顯示出一個警告信號,您應該知道...
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.
當然,你可能會通過其他地方尋找一個絕佳的投資機會。所以請查看這個我們預計將增長每股收益的公司免費列表。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.
請注意,本文中引用的市場回報反映了當前在美國交易所上市股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall ST的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall ST在提到的任何股票中均沒有持倉。
譯文內容由第三人軟體翻譯。